查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1386403

皮肤癌诊断与治疗市场报告：2030 年趋势、预测与竞争分析

Skin Cancer Diagnostics & Therapeutics Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

皮肤癌诊断和治疗的趋势和预测

预计到2030年，全球皮肤癌诊断和治疗市场将达到181亿美元，2024年至2030年年复合成长率为5.0%。市场的主要驱动因素是政府加强早期检测和皮肤癌治疗的倡议、活性化皮肤癌诊断和治疗的研发活动以及全球皮肤癌盛行率的增加。这与提高意识有关。全球皮肤癌诊断和治疗市场前景广阔，诊断和治疗市场充满机会。

皮肤癌诊断与治疗市场洞察

Lucintel 预测，由于非黑色素瘤病例数量不断增加，预计在预测期内非黑色素瘤将出现高速增长。这些皮肤癌始于皮肤细胞，癌变（恶性）的癌细胞可以生长并破坏附近的组织。

治疗仍然是该市场最大的部分。

由于北美皮肤癌的盛行率和发生率不断增加，在预测期内它可能仍然是最大的部分。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2. 未来哪个细分市场成长较快？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和业务风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球皮肤癌诊断与治疗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球皮肤癌诊断与治疗市场趋势（2018-2023）与预测（2024-2030）
  • 按癌症类型分類的全球皮肤癌诊断和治疗市场
    • 黑色素瘤
    • 非黑色素瘤
  • 按类型分類的全球皮肤癌诊断和治疗市场
    • 诊断
    • 治疗
    • 其他的

第4章2018-2030年分地区市场趋势及预测分析

  • 全球皮肤癌诊断与治疗市场（按地区）
  • 北美皮肤癌诊断与治疗市场
  • 欧洲皮肤癌诊断与治疗市场
  • 亚太皮肤癌诊断与治疗市场
  • 其他区域皮肤癌诊断与治疗市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 按癌症类型分類的全球皮肤癌诊断和治疗市场成长机会
    • 全球皮肤癌诊断和治疗市场成长机会（按类型）
    • 按地区分類的全球皮肤癌诊断和治疗市场成长机会
  • 全球皮肤癌诊断和治疗市场的新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球皮肤癌诊断和治疗市场的能力
    • 全球皮肤收购和合资
    • 认证和许可

第7章主要企业概况

  • AB Science
  • Abbott Laboratories
  • Amgen
  • AstraZeneca
  • Bristol-Myers Squibb
  • Castle Biosciences
  • Daiichi Sankyo
  • DAMAE Medical
  • DermTech
  • F. Hoffmann-La Roche
简介目录

Skin Cancer Diagnostics & Therapeutics Trends and Forecast

The future of the global skin cancer diagnostics & therapeutics market looks promising with opportunities in the diagnosis and therapeutic markets. The global skin cancer diagnostics & therapeutics market is expected to reach an estimated $18.1 billion by 2030 with a CAGR of 5.0% from 2024 to 2030. The major drivers for this market are increasing government initiatives for early detection and skin cancer treatment, rising research and development activities for skin cancer diagnostics and therapeutics, and growing incidences and rising awareness of skin cancer globally.

A more than 150-page report is developed to help in your business decisions.

Skin Cancer Diagnostics & Therapeutics by Segment

The study includes a forecast for the global skin cancer diagnostics & therapeutics by cancer type, type, and region.

Skin Cancer Diagnostics & Therapeutics Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]:

  • Melanoma
  • Non-Melanoma

Skin Cancer Diagnostics & Therapeutics Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Diagnosis
  • Therapeutics
  • Others

Skin Cancer Diagnostics & Therapeutics Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Skin Cancer Diagnostics & Therapeutics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies skin cancer diagnostics & therapeutics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the skin cancer diagnostics & therapeutics companies profiled in this report include-

  • Ab Science
  • Abbott Laboratories
  • Amgen
  • Astrazeneca
  • Bristol-Myers Squibb
  • Castle Biosciences
  • Daiichi Sankyo
  • Damae Medical
  • Dermtech
  • F. Hoffmann-La Roche

Skin Cancer Diagnostics & Therapeutics Market Insights

Lucintel forecasts that non-melanoma is expected to witness higher growth over the forecast period due to growing the increasing cases of non-melanoma as these skin cancer starts in skin cells and a cancerous (malignant) growth is a group of cancer cells that can grow into and destroy nearby tissue. it can also spread (metastasize) to other parts of the body, but this is rare with non-melanoma skin cancer.

Within this market, therapeutic will remain the largest segment.

North America will remain the largest segment over the forecast period due to the growing prevalence and incidence of skin cancers in this region.

Features of the Global Skin Cancer Diagnostics & Therapeutics Market

Market Size Estimates: Skin cancer diagnostics & therapeutics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Skin cancer diagnostics & therapeutics market size by cancer type, type, and region in terms of value ($B).

Regional Analysis: Skin cancer diagnostics & therapeutics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different cancer types, types, and regions for the skin cancer diagnostics & therapeutics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the skin cancer diagnostics & therapeutics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the skin cancer diagnostics & therapeutics market size?

Answer: The global skin cancer diagnostics & therapeutics market is expected to reach an estimated $18.1 billion by 2030.

Q.2 What is the growth forecast for skin cancer diagnostics & therapeutics market?

Answer: The global skin cancer diagnostics & therapeutics market is expected to grow with a cagr of 5.0% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the skin cancer diagnostics & therapeutics market?

Answer: The major drivers for this market are increasing government initiatives for early detection and skin cancer treatment, rising research and development activities for skin cancer diagnostics and therapeutics, and growing incidences and rising awareness of skin cancer globally.

Q4. What are the major segments for skin cancer diagnostics & therapeutics market?

Answer: The future of the skin cancer diagnostics & therapeutics market looks promising with opportunities in the diagnosis and therapeutic markets.

Q5. Who are the key skin cancer diagnostics & therapeutics market companies?

Answer: Some of the key skin cancer diagnostics & therapeutics companies are as follows:

  • AB Science
  • Abbott Laboratories
  • Amgen
  • AstraZeneca
  • Bristol-Myers Squibb
  • Castle Biosciences
  • Daiichi Sankyo
  • DAMAE Medical
  • DermTech
  • F. Hoffmann-La Roche

Q6. Which skin cancer diagnostics & therapeutics market segment will be the largest in future?

Answer: Lucintel forecasts that non-melanoma is expected to witness higher growth over the forecast period due to growing the increasing cases of non-melanoma as these skin cancer starts in skin cells and a cancerous (malignant) growth is a group of cancer cells that can grow into and destroy nearby tissue. it can also spread (metastasize) to other parts of the body, but this is rare with non-melanoma skin cancer.

Q7. In skin cancer diagnostics & therapeutics market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to the growing prevalence and incidence of skin cancers in this region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the skin cancer diagnostics & therapeutics market by cancer type (melanoma and non-melanoma), type (diagnosis, therapeutics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Skin Cancer Diagnostics & Therapeutics Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Skin Cancer Diagnostics & Therapeutics Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Skin Cancer Diagnostics & Therapeutics Market by Cancer Type
    • 3.3.1: Melanoma
    • 3.3.2: Non-melanoma
  • 3.4: Global Skin Cancer Diagnostics & Therapeutics Market by Type
    • 3.4.1: Diagnosis
    • 3.4.2: Therapeutics
    • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Skin Cancer Diagnostics & Therapeutics Market by Region
  • 4.2: North American Skin Cancer Diagnostics & Therapeutics Market
    • 4.2.2: North American Skin Cancer Diagnostics & Therapeutics Market by Type: Diagnosis, Therapeutics, and Others
  • 4.3: European Skin Cancer Diagnostics & Therapeutics Market
    • 4.3.1: European Skin Cancer Diagnostics & Therapeutics Market by Cancer Type: Melanoma and Non-melanoma
    • 4.3.2: European Skin Cancer Diagnostics & Therapeutics Market by Type: Diagnosis, Therapeutics, and Others
  • 4.4: APAC Skin Cancer Diagnostics & Therapeutics Market
    • 4.4.1: APAC Skin Cancer Diagnostics & Therapeutics Market by Cancer Type: Melanoma and Non-melanoma
    • 4.4.2: APAC Skin Cancer Diagnostics & Therapeutics Market by Type: Diagnosis, Therapeutics, and Others
  • 4.5: ROW Skin Cancer Diagnostics & Therapeutics Market
    • 4.5.1: ROW Skin Cancer Diagnostics & Therapeutics Market by Cancer Type: Melanoma and Non-melanoma
    • 4.5.2: ROW Skin Cancer Diagnostics & Therapeutics Market by Type: Diagnosis, Therapeutics, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Skin Cancer Diagnostics & Therapeutics Market by Cancer Type
    • 6.1.2: Growth Opportunities for the Global Skin Cancer Diagnostics & Therapeutics Market by Type
    • 6.1.3: Growth Opportunities for the Global Skin Cancer Diagnostics & Therapeutics Market by Region
  • 6.2: Emerging Trends in the Global Skin Cancer Diagnostics & Therapeutics Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Skin Cancer Diagnostics & Therapeutics Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Skin Cancer Diagnostics & Therapeutics Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: AB Science
  • 7.2: Abbott Laboratories
  • 7.3: Amgen
  • 7.4: AstraZeneca
  • 7.5: Bristol-Myers Squibb
  • 7.6: Castle Biosciences
  • 7.7: Daiichi Sankyo
  • 7.8: DAMAE Medical
  • 7.9: DermTech
  • 7.10: F. Hoffmann-La Roche